Drug Trial Radar · NCT06541262
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Oct 30, 2024
Primary completion
Nov 1, 2030
Study completion Nov 1, 2035
Sponsor
- Lead sponsor
- Milton S. Hershey Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of silmitasertib in combination with chemotherapy * Test the safety and tolerability of silmitasertib in combination with chemotherapy in subjects with cancer * To determine the activity of study treatments chosen based on: * How each subject responds to the study treatment * How long a subject lives without their disease returning/progressing
Conditions
- Neuroblastoma
- Ewing Sarcoma
- Osteosarcoma
- Rhabdomyosarcoma
- Liposarcoma
Interventions
SilmitasertibDrug
Capsules
IrinotecanDrug
IV
TemozolomideDrug
Oral or IV
VincristineDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 2 years plus 30 days
- Phase I- Number of Participants with Dose Limiting Toxicities to determine RP2DTime frame: 21 days
- Phase II- Determine the Overall Response Rate (ORR) of Participants using INRCTime frame: 2 years
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama/Children's of Alabama
Birmingham, Alabama · Recruiting
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
UC Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Rady Children's Hospital
San Diego, California · Recruiting
Connecticut Children's Hospital
Hartford, Connecticut · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
Arnold Palmer Hospital for Children
Orlando, Florida · Recruiting
All Children's Hospital Johns Hopkins Medicine
St. Petersburg, Florida · Recruiting
St. Joseph's Children's Hospital
Tampa, Florida · Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii · Recruiting
Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine
Louisville, Kentucky · Recruiting
Children's Hospital of Michigan/Wayne State University
Detroit, Michigan · Recruiting
Children's Mercy Hospitals and Clinics
Kansas City, Missouri · Recruiting
Cardinal Glennon Children's Medical Center
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania · Recruiting
Hasbro Children's Hospital
Providence, Rhode Island · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Monroe Carrell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee · Recruiting
Children's Medical Center
Dallas, Texas · Recruiting
Primary Children's Hospital
Salt Lake City, Utah · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
UHC Sainte-Justine
Montreal, Quebec, Canada · Recruiting
CIUSSS de l'Estrie-CHUS
Sherbrooke, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.